CSL Biotherapies Files Flu Vaccine BLA
This article was originally published in PharmAsia News
Executive Summary
Global influenza vaccine manufacturer CSL Biotherapies submitted a BLA March 30 seeking U.S. approval of its seasonal flu vaccine for healthy adults 18 and older, the company announced April 3
You may also be interested in...
Rhophylac Unapproved Use Claims Targeted In CBER Untitled Letter
ZLB Behring is falsely promoting an unapproved indication for the immune globulin product in an American Hospital Formulary Service fact sheet, FDA says.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).